United Immunity develops innovative pullulan‑based nanoparticles (PNPs and P‑LNPs) that use polysaccharide engineering to selectively deliver therapies to myeloid immune cells such as macrophages and dendritic cells. By directing drugs precisely to these key immune players, the company aims to create breakthrough treatments for cancer, infectious and autoimmune diseases, fibrosis, metabolic disorders, and more.
